Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Hady Ghanem, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Sherry A. Pierce, RN, BS, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 2627.

https://doi.org/10.1182/blood.V120.21.2627.2627

Published: 2012

Journal Articles

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Stefan Faderl, MD, Rajyalakshmi Luthra, Ph.D., William G. Wierda, MD, Ph.D., Alessandra Ferrajoli, Sherry A. Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2562.

https://doi.org/10.1182/blood.V120.21.2562.2562

Published: 2012

Journal Articles

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Elias J. Jabbour, MD, Naval G. Daver, MD, Tina (Xiao Qin) Dong, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, M.D., Hady Ghanem, MD, Stefan Faderl, MD, Gautam Borthakur, M.D., Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 2824.

https://doi.org/10.1182/blood.V120.21.2824.2824

Published: 2012

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, M.D., Deborah Thomas, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, John T Manning, MD, L. Jeffrey Medeiros, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Aziz Nazha, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Stefan Faderl, MD

Blood (2012) 120 (21): 3554.

https://doi.org/10.1182/blood.V120.21.3554.3554

Published: 2012

Journal Articles

Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Yanis Boumber, MD, PhD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Michael E. Rytting, MD, Marian R Love, Hongbo Lu, MMSC, Rebecca Garris, BSc, Jorge E. Cortes, MD, Susan O'Brien, M.D., Jan A. Burger, MD, PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD, PhD

Blood (2012) 120 (21): 3567.

https://doi.org/10.1182/blood.V120.21.3567.3567

Published: 2012

Journal Articles

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Blood (2012) 120 (21): 3572.

https://doi.org/10.1182/blood.V120.21.3572.3572

Published: 2012

Journal Articles

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

Olivia R. Deitcher, Stuart L. Goldberg, MD, Wendy Stock, MD, Gary J. Schiller, MD, John Lister, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD, Susan O'Brien, M.D.

Blood (2012) 120 (21): 4805.

https://doi.org/10.1182/blood.V120.21.4805.4805

Published: 2012

Journal Articles

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Nathalie Y Rosin, PhD, Stefan Koehrer, MD, Ekaterina Kim, MS, Susan O'Brien, M.D., William G. Wierda, MD, Ph.D., Deborah A. Thomas, MD, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Brian J. Lannutti, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3534.

https://doi.org/10.1182/blood.V120.21.3534.3534

Published: 2012

Journal Articles

Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights On Potential Preferential Formation of Ara-CTP Directly From Elacytarabine As Well As From Ara-C

Corinne Seng Yue, Varsha V. Gandhi, Ph.D., Susan O'Brien, M.D., Farhad Ravandi, MD, Tove Flem Jacobsen, Hubert Dirven, PhD, Steinar Hagen, PhD, Petter-Arnt Hals, PhD, Murray Ducharme, PhD

Blood (2012) 120 (21): 3547.

https://doi.org/10.1182/blood.V120.21.3547.3547

Published: 2012

Journal Articles

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

LM Poon, Patricia S Fox, MS, Barry I. Samuels, MD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Michael J. Keating, MD, Elias J. Jabbour, MD, Yvonne Hsu, Lynne V. Abruzzo, MD, PhD, Richard E. Champlin, Roland Bassett, Issa F. Khouri, MD

Blood (2012) 120 (21): 1977.

https://doi.org/10.1182/blood.V120.21.1977.1977

Published: 2012

Journal Articles

The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 72.

https://doi.org/10.1182/blood.V120.21.72.72

Published: 2012

Journal Articles

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Sherry A. Pierce, RN, BS, Moshe Talpaz, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 918.

https://doi.org/10.1182/blood.V120.21.918.918

Published: 2012

Journal Articles

Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

Susan O'Brien, M.D., Deborah A. Thomas, MD, Jeffrey L. Jorgensen, MD, PhD, Partow Kebriaei, M.D., Farhad Ravandi, MD, Monica Kwari, BSN, Stefan Faderl, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Sergernne York, RN, Rebecca Garris, BSc, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 671.

https://doi.org/10.1182/blood.V120.21.671.671

Published: 2012

Journal Articles

Is Chronic Lymphocytic Leukemia Still Incurable?

Michael J. Keating, MD, Constantine S Tam, William G. Wierda, MD, Ph.D., Susan O'Brien, M.D., Deborah A. Thomas, MD, Jorge E. Cortes, MD, Susan Lerner, MS, William Plunkett, PhD

Blood (2012) 120 (21): 3929.

https://doi.org/10.1182/blood.V120.21.3929.3929

Published: 2012

Journal Articles

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Steven M. Kornblau, MD, PhD, Stefan Faderl, MD, Alessandra Ferrajoli, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3774.

https://doi.org/10.1182/blood.V120.21.3774.3774

Published: 2012

Journal Articles

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Yin Cameron, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Hady Ghanem, MD, Tapan M. Kadia, M.D., Stefan Faderl, MD, Susan O'Brien, M.D., Michael S Mathisen, PharmD, Mark Brandt, BS, Naveen Pemmaraju, M.D., Deborah A. Thomas, MD, Joyce Bass, RN, Gautam Borthakur

Blood (2012) 120 (21): 3609.

https://doi.org/10.1182/blood.V120.21.3609.3609

Published: 2012

Journal Articles

Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)

Michael S Mathisen, PharmD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Hady Ghanem, MD, Naval G. Daver, MD, Sherry A. Pierce, RN, BS, Cynthia Lira, RN, Stefan Faderl, MD, Elias Jabbour, MD

Blood (2012) 120 (21): 3610.

https://doi.org/10.1182/blood.V120.21.3610.3610

Published: 2012

Journal Articles

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Rajyalakshmi Luthra, Ph.D., Alfonso Quintás-Cardama, M.D., Elias J. Jabbour, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 3781.

https://doi.org/10.1182/blood.V120.21.3781.3781

Published: 2012

NARROW

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights On Potential Preferential Formation of Ara-CTP Directly From Elacytarabine As Well As From Ara-C

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

Is Chronic Lymphocytic Leukemia Still Incurable?

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only